NCT04395989 2023-12-22
FUTURE-SUPER
Fudan University
Phase 2 Unknown
Clinical Trials
11 trialsNCT05928780 2023-07-03
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)
Fudan University
Phase 1/2 Unknown
NCT05556200 2023-04-12
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05670925 2023-02-28
A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
Fudan University
Phase 2 Unknown
NCT03805399 2022-08-10
FUTURE
Fudan University
Phase 1/2 Unknown
NCT05438706 2022-06-30
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
Fudan University
Phase 2 Unknown
NCT04129996 2022-01-11
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Fudan University
Phase 2 Unknown
NCT05088057 2021-10-21
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Jilin University
Phase 2 Unknown
NCT04907344 2021-05-28
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Unknown
NCT04676997 2020-12-21
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT04213898 2019-12-30
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Henan Cancer Hospital
Phase 1/2 Unknown